Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
公司代碼ACON
公司名稱Aclarion Inc
上市日期Apr 22, 2022
CEONess (Brent)
員工數量6
證券類型Ordinary Share
年結日Apr 22
公司地址8181 Arista Place
城市BROOMFIELD
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編80021
電話18332752266
網址https://aclarion.com/
公司代碼ACON
上市日期Apr 22, 2022
CEONess (Brent)